WCM Investment Management LLC Sells 3,590 Shares of Insmed Incorporated (NASDAQ:INSM)

WCM Investment Management LLC reduced its position in shares of Insmed Incorporated (NASDAQ:INSM) by 2.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 144,740 shares of the biopharmaceutical company’s stock after selling 3,590 shares during the quarter. WCM Investment Management LLC owned 0.08% of Insmed worth $9,968,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of INSM. V Square Quantitative Management LLC bought a new stake in shares of Insmed during the third quarter valued at approximately $30,000. GAMMA Investing LLC boosted its stake in Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the last quarter. Spire Wealth Management bought a new stake in shares of Insmed in the 4th quarter worth $47,000. Exchange Traded Concepts LLC raised its stake in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Insmed by 2,348.8% during the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,879 shares in the last quarter.

Insmed Trading Down 1.0 %

Insmed stock opened at $79.95 on Monday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $82.04. The firm has a market capitalization of $14.30 billion, a price-to-earnings ratio of -14.41 and a beta of 1.11. The firm has a 50 day moving average of $72.88 and a 200 day moving average of $73.09.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares of the company’s stock, valued at $26,885,606.40. This represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 1,066 shares of Insmed stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.72, for a total value of $67,925.52. Following the sale, the chief financial officer now directly owns 118,863 shares in the company, valued at $7,573,950.36. This trade represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 401,030 shares of company stock valued at $30,993,629 over the last three months. Corporate insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Truist Financial reiterated a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday. Morgan Stanley increased their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Finally, Guggenheim increased their price target on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $85.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.